ADMA Adma Biologics Inc

Price (delayed)

$4.05

Market cap

$900.21M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.24

Enterprise value

$976.26M

ADMA Biologics is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at ...

Highlights
ADMA's revenue has surged by 94% year-on-year and by 18% since the previous quarter
The EPS has surged by 50% year-on-year and by 27% since the previous quarter
The equity has increased by 15% year-on-year but it has declined by 4.2% since the previous quarter
ADMA's quick ratio is down by 13% YoY
The company's debt rose by 4.4% YoY

Key stats

What are the main financial stats of ADMA
Market
Shares outstanding
222.27M
Market cap
$900.21M
Enterprise value
$976.26M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
6.18
Price to sales (P/S)
4.94
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
5.37
Earnings
Revenue
$181.89M
EBIT
-$25.68M
EBITDA
-$18.12M
Free cash flow
-$61.23M
Per share
EPS
-$0.24
Free cash flow per share
-$0.28
Book value per share
$0.66
Revenue per share
$0.82
TBVPS
$1.52
Balance sheet
Total assets
$340.79M
Total liabilities
$195.13M
Debt
$145.26M
Equity
$145.65M
Working capital
$227.36M
Liquidity
Debt to equity
1
Current ratio
7.19
Quick ratio
2.61
Net debt/EBITDA
-4.2
Margins
EBITDA margin
-10%
Gross margin
26.5%
Net margin
-26.2%
Operating margin
-13.9%
Efficiency
Return on assets
-14.8%
Return on equity
-37.2%
Return on invested capital
-7.1%
Return on capital employed
-8.4%
Return on sales
-14.1%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

ADMA stock price

How has the Adma Biologics stock price performed over time
Intraday
1%
1 week
-0.74%
1 month
22.73%
1 year
102.5%
YTD
4.38%
QTD
22.36%

Financial performance

How have Adma Biologics's revenue and profit performed over time
Revenue
$181.89M
Gross profit
$48.12M
Operating income
-$25.36M
Net income
-$47.68M
Gross margin
26.5%
Net margin
-26.2%
ADMA's revenue has surged by 94% year-on-year and by 18% since the previous quarter
Adma Biologics's operating margin has surged by 77% YoY and by 45% QoQ
The company's net margin has surged by 69% YoY and by 39% QoQ
Adma Biologics's operating income has surged by 56% YoY and by 36% QoQ

Growth

What is Adma Biologics's growth rate over time

Valuation

What is Adma Biologics stock price valuation
P/E
N/A
P/B
6.18
P/S
4.94
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
5.37
The EPS has surged by 50% year-on-year and by 27% since the previous quarter
The price to book (P/B) is 34% higher than the last 4 quarters average of 4.6 and 31% higher than the 5-year quarterly average of 4.7
The equity has increased by 15% year-on-year but it has declined by 4.2% since the previous quarter
ADMA's revenue has surged by 94% year-on-year and by 18% since the previous quarter
ADMA's price to sales (P/S) is 20% higher than its last 4 quarters average of 4.1 but 19% lower than its 5-year quarterly average of 6.1

Efficiency

How efficient is Adma Biologics business performance
The return on sales has surged by 80% year-on-year and by 53% since the previous quarter
The company's return on invested capital has surged by 69% YoY and by 46% QoQ
The company's return on assets has surged by 50% YoY and by 30% QoQ
ADMA's ROE is up by 43% YoY and by 30% QoQ

Dividends

What is ADMA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ADMA.

Financial health

How did Adma Biologics financials performed over time
Adma Biologics's total assets is 75% more than its total liabilities
ADMA's quick ratio is down by 13% YoY
Adma Biologics's total assets has increased by 11% YoY but it has decreased by 2.2% from the previous quarter
The equity has increased by 15% year-on-year but it has declined by 4.2% since the previous quarter
Adma Biologics's debt to equity has decreased by 9% YoY but it has increased by 5% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.